Opendata, web and dolomites

AllergyVAX SIGNED

Next generation allergen immunotherapy based on specifically modified recombinant hypoallergens

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AllergyVAX project word cloud

Explore the words cloud of the AllergyVAX project. It provides you a very rough idea of what is the project "AllergyVAX" about.

modified    economic    hypoallergens    monthly    proteins    allergies    tolerated    symptoms    tablets    allergens    basis    days    compromising    iib    tolerate    allergen    natural    tests    preclinical    release    fold    relief    injectable    allergyvax    dozens    popularity    disease    dog    created    human    immunotherapy    avoiding    building    usually    symptom    tolerance    allergic    trigger    hypoallergen    shorten    months    asthma    reactions    pollen    causes    platform    alleviates    birch    small    global    million    social    school    treatment    rbet    few    relatively    dm    risk    efficacy    injections    managed    medication    grass    people    advancing    billion    training    reduce    bet    daily    immune    takes    patients    modifying    pipeline    missed    histamine    iia    serious    ait    symptomatic    immunological    shown    transition    seamless    clinically    dose    modifications    desired    maximum    candidates    launch    immunogenicity    date    clinical    allergy    establishing    drugs    drops    mice    rhinitis    horse    burden    peanut    temporarily    trial   

Project "AllergyVAX" data sheet

The following table provides information about the project.

Coordinator
DESENTUM OY 

Organization address
address: RUNEBERGINKATU 49 A 22 LEXWELL OY
city: HELSINKI
postcode: 260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 3˙684˙750 €
 EC max contribution 1˙885˙000 € (51%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DESENTUM OY FI (HELSINKI) coordinator 1˙885˙000.00

Map

 Project objective

Allergy is a rapidly increasing, global problem that already affects 1 billion people and causes significant social and economic burden. In Europe, allergic rhinitis and asthma cause more than 100 million missed work and school days per year. Allergy is usually managed by avoiding the allergen or by medication that temporarily alleviates the symptoms. The only disease-modifying treatment available to date is allergen immunotherapy (AIT) where long-term symptom relief is achieved by training the immune system to tolerate allergens. However, typical AIT takes 3-5 years, involves monthly injections or daily drops/tablets and has the risk of serious allergic reactions during treatment. Thus, the popularity of AIT is still relatively low compared to symptomatic drugs. We have developed a platform technology for creating modified hypoallergens to be used in AIT. It is based on making small, highly targeted modifications to allergen proteins that reduce their ability to trigger allergic reactions during treatment without compromising their efficacy in building tolerance to natural allergens. With these modified hypoallergens, we expect to shorten the injectable AIT treatment from dozens of injections over 3 years to just 3-6 injections over a few months. From the clinically important major birch pollen allergen Bet v 1 we have created rBet v 1 dm hypoallergen. In preclinical tests it has shown 100-fold reduction in histamine release compared to natural allergens and induced similar immunological responses in mice that are desired in human AIT. In the AllergyVAX project we will test rBet v 1 dm for maximum tolerated dose and immunogenicity in allergic patients in a phase I/IIa clinical trial. The project will facilitate seamless transition to phase IIb-III clinical development, establishing a basis for product launch with selected partners and advancing other hypoallergens in the pipeline, including product candidates for grass pollen, dog, horse and peanut allergies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALLERGYVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALLERGYVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

Reuse as a service (2019)

Reusable packaging as a service for e-commerce

Read More